Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945

Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS). While multiple effective immunomodulatory therapies for MS exist today, they lack the scope of promoting CNS repair, in particular remyelination. Microglia play a pivotal role in regulating myelination processes, and the colony-stimulating factor 1 (CSF-1) pathway is a key regulator for microglia differentiation and survival. Here, we investigated the effects of the CSF-1 receptor kinase inhibitor, BLZ945, on central myelination processes in the 5-week murine cuprizone model by non-invasive and longitudinal magnetic resonance imaging (MRI) and histology. Therapeutic 2-week BLZ945 treatment caused a brain region-specific enhancement of remyelination in the striatum/cortex, which was absent in the corpus callosum/external capsule. This beneficial effect correlated positively with microglia reduction, increased oligodendrocytes and astrogliosis. Prophylactic BLZ945 treatment prevented excessive demyelination in the corpus callosum by reducing microglia and increasing oligondendrocytes. In the external capsule oligodendrocytes were depleted but not microglia and a buildup of myelin debris and axonal damage was observed. A similar microglial dysfunction in the external capsule with an increase of myelin debris was obvious in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice treated with cuprizone. Finally, therapeutic BLZ945 treatment did not change the disease course in experimental autoimmune encephalomyelitis mice, a peripherally driven neuroinflammation model. Taken together, our data suggest that a short-term therapeutic inhibition of the CSF-1 receptor pathway by BLZ945 in the murine cuprizone model enhances central remyelination by modulating neuroinflammation. Thus, microglia-modulating therapies could be considered clinically for promoting myelination in combination with standard-of-care treatments in MS patients.

[1]  Yang-tao He,et al.  Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination , 2015, Neuroscience Bulletin.

[2]  Samuel Bernard,et al.  Dynamics of Oligodendrocyte Generation and Myelination in the Human Brain , 2014, Cell.

[3]  Absence of CCL2 and CCL3 Ameliorates Central Nervous System Grey Matter But Not White Matter Demyelination in the Presence of an Intact Blood–Brain Barrier , 2015, Molecular Neurobiology.

[4]  J. Thiessen,et al.  Quantitative MRI and ultrastructural examination of the cuprizone mouse model of demyelination , 2013, NMR in biomedicine.

[5]  Tracy J. Yuen,et al.  M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination , 2013, Nature Neuroscience.

[6]  J Hennig,et al.  RARE imaging: A fast imaging method for clinical MR , 1986, Magnetic resonance in medicine.

[7]  C. Wegner,et al.  Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination , 2012, Acta Neuropathologica.

[8]  Jens Frahm,et al.  Multicontrast MRI of remyelination in the central nervous system , 2005, NMR in biomedicine.

[9]  M. Day,et al.  Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice , 2012, Neuroscience.

[10]  Sveinung Fjær,et al.  Deep Gray Matter Demyelination Detected by Magnetization Transfer Ratio in the Cuprizone Model , 2013, PloS one.

[11]  Hai-tao Zhu,et al.  M2 microglia promotes neurogenesis and oligodendrogenesis from neural stem/progenitor cells via the PPARγ signaling pathway , 2017, Oncotarget.

[12]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[13]  A. Najafi,et al.  Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. , 2016, Brain : a journal of neurology.

[14]  B. Castellano,et al.  Astrocyte‐targeted production of interleukin‐6 reduces astroglial and microglial activation in the cuprizone demyelination model: Implications for myelin clearance and oligodendrocyte maturation , 2016, Glia.

[15]  C. Schmitz,et al.  Combination of cuprizone and experimental autoimmune encephalomyelitis to study inflammatory brain lesion formation and progression , 2017, Glia.

[16]  J. Pollard,et al.  Absence of Colony Stimulation Factor-1 Receptor Results in Loss of Microglia, Disrupted Brain Development and Olfactory Deficits , 2011, PloS one.

[17]  D Matthaei,et al.  Dynamic digital subtraction imaging using fast low-angle shot MR movie sequence. , 1986, Radiology.

[18]  A. Maurelli,et al.  Evolution of Bacterial Pathogens Within the Human Host. , 2016, Microbiology spectrum.

[19]  Markus Rudin,et al.  MRI signature in a novel mouse model of genetically induced adult oligodendrocyte cell death , 2012, NeuroImage.

[20]  H. Neumann,et al.  CXCL10 Triggers Early Microglial Activation in the Cuprizone Model , 2015, The Journal of Immunology.

[21]  Inki Kim,et al.  Disparate roles of zinc in chemical hypoxia-induced neuronal death , 2015, Front. Cell. Neurosci..

[22]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[23]  A. Najafi,et al.  Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice , 2015, Journal of Neuroinflammation.

[24]  R. Ransohoff.  A polarizing question: do M1 and M2 microglia exist? , 2016, Nature Neuroscience.

[25]  C. Trebst,et al.  Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system , 2011, Brain, Behavior, and Immunity.

[26]  Jennifer Luebke,et al.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation , 2015, Nature Neuroscience.

[27]  Mariana Vargas-Caballero,et al.  Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology , 2016, Brain : a journal of neurology.

[28]  K. Green,et al.  Characterizing Newly Repopulated Microglia in the Adult Mouse: Impacts on Animal Behavior, Cell Morphology, and Neuroinflammation , 2015, PloS one.

[29]  C. Branch,et al.  Phenotypic characterization of a Csf1r haploinsufficient mouse model of adult-onset leukodystrophy with axonal spheroids and pigmented glia (ALSP) , 2015, Neurobiology of Disease.

[30]  Sjef Copray,et al.  The cuprizone animal model: new insights into an old story , 2009, Acta Neuropathologica.

[31]  M. Wiesmann,et al.  Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite , 2015, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  K. Tenbrock,et al.  Neurodegeneration Triggers Peripheral Immune Cell Recruitment into the Forebrain , 2016, The Journal of Neuroscience.

[33]  J. Relton,et al.  Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival , 2013, The Journal of experimental medicine.

[34]  Peter K. Stys,et al.  Inefficient clearance of myelin debris by microglia impairs remyelinating processes , 2015, Journal of Experimental Medicine.

[35]  D. Hafler,et al.  Multiple sclerosis. , 2012, The Journal of clinical investigation.

[36]  K. Green,et al.  Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus , 2015, The Journal of Neuroscience.

[37]  Brian L. West,et al.  Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain , 2014, Neuron.

[38]  M. Colonna,et al.  TREM2 sustains microglial expansion during aging and response to demyelination. , 2015, The Journal of clinical investigation.

[39]  T. Wisniewski,et al.  The Role of TREM2 in Alzheimer’s Disease and Other Neurological Disorders , 2014, Journal of Alzheimer's disease & Parkinsonism.

[40]  O. Ciccarelli,et al.  Exploring the origins of grey matter damage in multiple sclerosis , 2015, Nature Reviews Neuroscience.

[41]  R. Franco,et al.  Alternatively activated microglia and macrophages in the central nervous system , 2015, Progress in Neurobiology.

[42]  H. Völzke,et al.  Microglia ablation alleviates myelin-associated catatonic signs in mice , 2017, The Journal of clinical investigation.

[43]  M. Prinz,et al.  Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood , 2017, Acta Neuropathologica.

[44]  Elisa Cerutti,et al.  Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and β-catenin , 2009, Nature Immunology.

[45]  Oded Gonen,et al.  Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 9.4 T , 2008, Magnetic Resonance Materials in Physics, Biology and Medicine.

[46]  M. Stangel,et al.  Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned , 2014, Front. Cell. Neurosci..

[47]  M. Daly,et al.  Variant TREM2 as risk factor for Alzheimer's disease. , 2013, The New England journal of medicine.

[48]  K. Myhr,et al.  The cuprizone model for demyelination , 2008, Acta neurologica Scandinavica. Supplementum.

[49]  Cuprizone-Induced Demyelination as a Tool to Study Remyelination and Axonal Protection , 2013, Journal of Molecular Neuroscience.

[50]  M. Xie,et al.  TREM2 regulates microglial cell activation in response to demyelination in vivo , 2015, Acta Neuropathologica.

[51]  W. Baumgärtner,et al.  Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. , 2013, Brain : a journal of neurology.

[52]  S. Hauser,et al.  Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial , 2017, The Lancet.

[53]  B. West,et al.  Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. , 2015, Brain : a journal of neurology.

[54]  V. Perry,et al.  CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves , 2016, Scientific Reports.

[55]  W. Brück,et al.  Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[56]  Ludovico Minati,et al.  In vivo quantitative magnetization transfer imaging correlates with histology during de‐ and remyelination in cuprizone‐treated mice , 2015, NMR in biomedicine.

[57]  J. Kong,et al.  Quetiapine Inhibits Microglial Activation by Neutralizing Abnormal STIM1-Mediated Intercellular Calcium Homeostasis and Promotes Myelin Repair in a Cuprizone-Induced Mouse Model of Demyelination , 2015, Front. Cell. Neurosci..

[58]  H. Lassmann,et al.  Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. , 2017, JCI insight.